Literature DB >> 31006110

Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2B6 and Efavirenz-Containing Antiretroviral Therapy.

Zeruesenay Desta1, Roseann S Gammal2,3, Li Gong4, Michelle Whirl-Carrillo4, Aditya H Gaur5, Chonlaphat Sukasem6,7, Jennifer Hockings8, Alan Myers9, Marelize Swart1, Rachel F Tyndale10, Collen Masimirembwa11, Otito F Iwuchukwu12, Sanika Chirwa13, Jeffrey Lennox14, Andrea Gaedigk15, Teri E Klein4, David W Haas13,16.   

Abstract

The HIV type-1 nonnucleoside reverse transcriptase inhibitor, efavirenz, is widely used to treat HIV type-1 infection. Efavirenz is predominantly metabolized into inactive metabolites by cytochrome P450 (CYP)2B6, and patients with certain CYP2B6 genetic variants may be at increased risk for adverse effects, particularly central nervous system toxicity and treatment discontinuation. We summarize the evidence from the literature and provide therapeutic recommendations for efavirenz prescribing based on CYP2B6 genotypes.
© 2019 The Authors Clinical Pharmacology & Therapeutics  © 2019 American Society for Clinical Pharmacology and Therapeutics.

Entities:  

Mesh：

Substances：

Year:  2019        PMID： 31006110      PMCID： PMC6739160          DOI： 10.1002/cpt.1477

Source DB:  PubMed          Journal:  Clin Pharmacol Ther        ISSN： 0009-9236            Impact factor:   6.875


  35 in total

1.  Long-term efavirenz autoinduction and its effect on plasma exposure in HIV patients.

Authors:  E Ngaimisi; S Mugusi; O M Minzi; P Sasi; K-D Riedel; A Suda; N Ueda; M Janabi; F Mugusi; W E Haefeli; J Burhenne; E Aklillu
Journal:  Clin Pharmacol Ther       Date:  2010-09-29       Impact factor: 6.875

2.  Efavirenz pharmacokinetics in HIV-1-infected children are associated with CYP2B6-G516T polymorphism.

Authors:  Akihiko Saitoh; Courtney V Fletcher; Richard Brundage; Carmelita Alvero; Terrence Fenton; Karen Hsia; Stephen A Spector
Journal:  J Acquir Immune Defic Syndr       Date:  2007-07-01       Impact factor: 3.731

3.  A natural CYP2B6 TATA box polymorphism (-82T--> C) leading to enhanced transcription and relocation of the transcriptional start site.

Authors:  Jörg Zukunft; Thomas Lang; Tanja Richter; Karen I Hirsch-Ernst; Andreas K Nussler; Kathrin Klein; Matthias Schwab; Michel Eichelbaum; Ulrich M Zanger
Journal:  Mol Pharmacol       Date:  2005-02-18       Impact factor: 4.436

4.  Influence of CYP2B6 polymorphism on plasma and intracellular concentrations and toxicity of efavirenz and nevirapine in HIV-infected patients.

Authors:  Margalida Rotger; Sara Colombo; Hansjakob Furrer; Gabriela Bleiber; Thierry Buclin; Belle L Lee; Olivia Keiser; Jérôme Biollaz; Laurent Décosterd; Amalio Telenti
Journal:  Pharmacogenet Genomics       Date:  2005-01       Impact factor: 2.089

5.  Efavirenz plasma levels can predict treatment failure and central nervous system side effects in HIV-1-infected patients.

Authors:  C Marzolini; A Telenti; L A Decosterd; G Greub; J Biollaz; T Buclin
Journal:  AIDS       Date:  2001-01-05       Impact factor: 4.177

6.  Predictive value of known and novel alleles of CYP2B6 for efavirenz plasma concentrations in HIV-infected individuals.

Authors:  M Rotger; H Tegude; S Colombo; M Cavassini; H Furrer; L Décosterd; J Blievernicht; T Saussele; H F Günthard; M Schwab; M Eichelbaum; A Telenti; U M Zanger
Journal:  Clin Pharmacol Ther       Date:  2007-01-18       Impact factor: 6.875

7.  Effect of CYP2B6, ABCB1, and CYP3A5 polymorphisms on efavirenz pharmacokinetics and treatment response: an AIDS Clinical Trials Group study.

Authors:  Heather J Ribaudo; Huan Liu; Matthias Schwab; Elke Schaeffeler; Michel Eichelbaum; Alison A Motsinger-Reif; Marylyn D Ritchie; Ulrich M Zanger; Edward P Acosta; Gene D Morse; Roy M Gulick; Gregory K Robbins; David Clifford; David W Haas
Journal:  J Infect Dis       Date:  2010-09-01       Impact factor: 5.226

8.  Aberrant splicing caused by single nucleotide polymorphism c.516G>T [Q172H], a marker of CYP2B6*6, is responsible for decreased expression and activity of CYP2B6 in liver.

Authors:  Marco H Hofmann; Julia K Blievernicht; Kathrin Klein; Tanja Saussele; Elke Schaeffeler; Matthias Schwab; Ulrich M Zanger
Journal:  J Pharmacol Exp Ther       Date:  2008-01-02       Impact factor: 4.030

9.  Glucuronidation of the antiretroviral drug efavirenz by UGT2B7 and an in vitro investigation of drug-drug interaction with zidovudine.

Authors:  Anne-Sophie Bélanger; Patrick Caron; Mario Harvey; Peter A Zimmerman; Rajeev K Mehlotra; Chantal Guillemette
Journal:  Drug Metab Dispos       Date:  2009-06-01       Impact factor: 3.922

10.  Impact of CYP2B6 polymorphism on hepatic efavirenz metabolism in vitro.

Authors:  Zeruesenay Desta; Tanja Saussele; Bryan Ward; Julia Blievernicht; Lang Li; Kathrin Klein; David A Flockhart; Ulrich M Zanger
Journal:  Pharmacogenomics       Date:  2007-06       Impact factor: 2.533
View more
  40 in total

1.  Implications of Efavirenz Pharmacogenetics When Switching From Efavirenz- to Dolutegravir-containing Antiretroviral Regimens.

Authors:  David W Haas; Edward P Acosta
Journal:  Clin Infect Dis       Date:  2021-05-18       Impact factor: 9.079

2.  Sources of Interindividual Variability.

Authors:  Yvonne S Lin; Kenneth E Thummel; Brice D Thompson; Rheem A Totah; Christi W Cho
Journal:  Methods Mol Biol       Date:  2021

Review 3.  Pharmacogenetics and Precision Medicine Approaches for the Improvement of COVID-19 Therapies.

Authors:  Mohitosh Biswas; Nares Sawajan; Thanyada Rungrotmongkol; Kamonpan Sanachai; Maliheh Ershadian; Chonlaphat Sukasem
Journal:  Front Pharmacol       Date:  2022-02-18       Impact factor: 5.810

4.  Influence of CYP2B6 and CYP3A4 polymorphisms on the virologic and immunologic responses of patients treated with efavirenz-containing regimen.

Authors:  Yaya Kassogue; Brehima Diakite; Mamoudou Maiga; Oumar Kassogue; Issa Konate; Kadidiatou Tamboura; Fousseyni Diarra; Zoumana Diarra; Mahamadou Karamoko Sawadogo; Yaya Goita; Sidi Boula Sissoko; Adama Seydou Sissoko; Nouhoum Guirou; Hind Dehbi; Sellama Nadifi; Sekou Bah; Cheick Bougadari Traore; Bakarou Kamate; Sounkalo Dao; Guimogo Dolo
Journal:  Pharmacogenet Genomics       Date:  2022-06-22       Impact factor: 2.000

5.  Quantitative Prediction of Drug Interactions Caused by Cytochrome P450 2B6 Inhibition or Induction.

Authors:  Veronica Di Paolo; Francesco Maria Ferrari; Italo Poggesi; Luigi Quintieri
Journal:  Clin Pharmacokinet       Date:  2022-07-20       Impact factor: 5.577

Review 6.  The Clinical Pharmacogenetics Implementation Consortium: 10 Years Later.

Authors:  Mary V Relling; Teri E Klein; Roseann S Gammal; Michelle Whirl-Carrillo; James M Hoffman; Kelly E Caudle
Journal:  Clin Pharmacol Ther       Date:  2019-11-05       Impact factor: 6.875

7.  Pharmacokinetics and phenotyping properties of the Basel phenotyping cocktail combination capsule in healthy male adults.

Authors:  Claudia Suenderhauf; Benjamin Berger; Maxim Puchkov; Yasmin Schmid; Sabine Müller; Jörg Huwyler; Manuel Haschke; Stephan Krähenbühl; Urs Duthaler
Journal:  Br J Clin Pharmacol       Date:  2019-12-12       Impact factor: 4.335

Review 8.  Pharmacogenomics of Antiretroviral Drug Metabolism and Transport.

Authors:  Zaikuan J Yu; Eric P Mosher; Namandjé N Bumpus
Journal:  Annu Rev Pharmacol Toxicol       Date:  2020-09-22       Impact factor: 13.820

9.  Circulating miRNAs as Biomarkers for CYP2B6 Enzyme Activity.

Authors:  Joseph Ipe; Rudong Li; Ingrid F Metzger; Jessica Bo Li Lu; Brandon T Gufford; Zeruesenay Desta; Yunlong Liu; Todd C Skaar
Journal:  Clin Pharmacol Ther       Date:  2020-10-05       Impact factor: 6.875

10.  Novel associations between CYP2B6 polymorphisms, perioperative methadone metabolism and clinical outcomes in children.

Authors:  Senthil Packiasabapathy; Blessed W Aruldhas; Pengyue Zhang; Brian R Overholser; Sara K Quinney; Senthilkumar Sadhasivam
Journal:  Pharmacogenomics       Date:  2021-06-08       Impact factor: 2.533
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.